Topiramate Suppliers & Bulk Manufacturers
Available Forms: Tablet / Capsule / Oral solution
Available Strengths: 25 mg, 50 mg, 100 mg, 200 mg, 25 mg/5 mL
Reference Brands: Topamax (USA/EU), Trokendi XR (USA)
Category:
Neurology
Topiramate is available in Tablet / Capsule / Oral solution
and strengths such as 25 mg, 50 mg, 100 mg, 200 mg, 25 mg/5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Topiramate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Topiramate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Topiramate, marketed under the brand name Topamax and other brand names, is an orally administered medication primarily used for the management of epilepsy and the prevention of migraine headaches. In epilepsy, topiramate is indicated for the treatment of generalized tonic-clonic seizures as well as partial-onset or focal seizures, helping to reduce seizure frequency and improve overall seizure control. Its broad-spectrum antiepileptic activity makes it suitable for use in both adult and pediatric patients.
Topiramate works through multiple mechanisms, including modulation of voltage-gated sodium channels, enhancement of gamma-aminobutyric acid (GABA) activity, inhibition of excitatory glutamate receptors, and weak inhibition of carbonic anhydrase enzymes. This multi-targeted approach contributes to its effectiveness in controlling abnormal neuronal activity and preventing migraine attacks.
In addition to its approved uses, topiramate has been employed off-label for conditions such as alcohol dependence and essential tremor, demonstrating its versatility in neurological and behavioral disorders. Its oral formulation allows for convenient administration, and dosage can be adjusted according to patient needs and tolerability. Topiramate is considered a valuable option for long-term management of seizures and migraine prevention, providing sustained therapeutic benefit with careful monitoring.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing